Optimization of Positive End Expiratory Pressure by Use of Pulmonary Ultrasound for Patients With Blunt Chest Trauma Treated by Non-Invasive Ventilation (Opti-PEP).

Sponsor
University Hospital, Montpellier (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06072339
Collaborator
(none)
40
2
12.2

Study Details

Study Description

Brief Summary

This is an open-label, randomized controlled study comparing two non-invasive ventilation initiation strategies.Patients may be included if they present with acute respiratory failure related to blunt chest trauma.The intervention group will benefit from the use by the physiotherapist of pulmonary ultrasound for the adjustment of Positive End Expiratory Pressure (PEEP) during the 1st session. The conventional group will benefit from the non-invasive ventilation according to the current care.

Condition or Disease Intervention/Treatment Phase
  • Other: Lung Ultrasound for PEEP setting
  • Procedure: Non invasive ventilation session
  • Biological: Arterial blood gas
  • Other: Interview on pain and comfort
N/A

Detailed Description

This is an open-label, randomized controlled study comparing two non-invasive ventilation initiation strategies. Patients may be included if they are admitted to intensive care unit or continuing care unit and present with acute respiratory failure related to blunt chest trauma. We will not include patients with another indication for non-invasive ventilation, immediately needing invasive ventilation, a contraindication to non invasive ventilation or an estimated length of stay less than or equal to 48 hours.

Both groups will be treated with non-ivasive ventilation according to the medical prescription. The intervention group will benefit from the use by the physiotherapist of pulmonary ultrasound for the adjustment of PEEP during the 1st session. The conventional group will benefit from the non-invasive ventilation according to the usual care. The other non-invasive ventilation settings will be chosen with the same method in both groups.

The main endpoint will be the PaO2/FiO2 ratio (Arterial oxygen pressure / inspired fraction of oxygen) after 30 min of non-invasive ventilation treatment. This ratio is the best reflection of the patient oxygenation and currently used for respiratory therapies studies.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
open-labeled, controlled, randomized studyopen-labeled, controlled, randomized study
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Optimization of Positive End Expiratory Pressure by Use of Pulmonary Ultrasound for Patients With Blunt Chest Trauma Treated by Non-Invasive Ventilation : Randomized Controlled Study (Opti-PEP).
Anticipated Study Start Date :
Oct 1, 2023
Anticipated Primary Completion Date :
Oct 1, 2024
Anticipated Study Completion Date :
Oct 7, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Experimental

The intervention group will benefit from the physiotherapist's use of lung ultrasound for the PEEP adjustment during the first NIV session.

Other: Lung Ultrasound for PEEP setting
NIV is started and adjusted by the physiotherapist. For the adjustment of PEEP, the ultrasound probe is placed on the thorax, facing the intercostal space having obtained the highest score during the initial LUS (synonym of the worst pulmonary aeration) and the images observed in real time. PEEP is increased until the physiotherapist cannot see any additional benefit on pulmonary aeration or appearance of a patient discomfort or an increasing of air leaks.

Procedure: Non invasive ventilation session
The session will be done via a mouthpiece preferably, or a face mask if it is impossible for the patient to close their mouth properly or to hold the mouthpiece. The duration of the NIV session will be defined by the prescribing doctor (usually between 30 and 60 minutes), without being able to be less than 30 minutes. The session will be stopped in the event of the appearance of one of the contraindications to NIV mentioned above.

Biological: Arterial blood gas
Arterial blood gas will be done at inclusion, at Visit 1 (at the 30th minute from the start of the 1st Non-invasive ventilation session) and at Visit 2 (at the 60th minute from the start of the 1st Non-invasive ventilation session) in both groups of patients in order to calculate the Pa02/Fi02 ratio.

Other: Interview on pain and comfort
The investigator physiotherapist interviews the participant to measure pain and comfort scores using a visual analogue scale (score from 0 to 10).

Active Comparator: Control

The conventional group will benefit from the NIV under the current terms.

Procedure: Non invasive ventilation session
The session will be done via a mouthpiece preferably, or a face mask if it is impossible for the patient to close their mouth properly or to hold the mouthpiece. The duration of the NIV session will be defined by the prescribing doctor (usually between 30 and 60 minutes), without being able to be less than 30 minutes. The session will be stopped in the event of the appearance of one of the contraindications to NIV mentioned above.

Biological: Arterial blood gas
Arterial blood gas will be done at inclusion, at Visit 1 (at the 30th minute from the start of the 1st Non-invasive ventilation session) and at Visit 2 (at the 60th minute from the start of the 1st Non-invasive ventilation session) in both groups of patients in order to calculate the Pa02/Fi02 ratio.

Other: Interview on pain and comfort
The investigator physiotherapist interviews the participant to measure pain and comfort scores using a visual analogue scale (score from 0 to 10).

Outcome Measures

Primary Outcome Measures

  1. PaO2/FiO2 ratio (Arterial oxygen pressure / inspired oxygen fraction) in both groups [at the 30th minute from the start of the 1st Non-invasive ventilation session]

    PaO2/FiO2 ratio (Arterial oxygen pressure / inspired oxygen fraction) in both groups. This PaO2/FiO2 ratio is now the benchmark for qualifying the severity of the respiratory impairment or measuring the response to a mechanical ventilation strategy aimed at improving oxygenation.

Secondary Outcome Measures

  1. Comparaison of the Lung Ultrasound Score (LUS) in both groups [at the 30th minute from the start of the 1st Non-invasive ventilation session]

    Comparaison of the Lung Ultrasound Score (LUS) in both groups. The LUS ranges from 0 to 36. Rib cage is divided into 12 areas (6 for each side) and each area is assessed according to the following scale: 0: Normal aeration corresponding to presence of lung sliding with A lines or fewer than two isolated B lines Moderate loss of lung aeration corresponding to multiple well-defined B lines or spaced ultrasound lung called 'cornet-tail artifact" Severe loss of lung aeration corresponding to multiple coalescent B lines or multiple abutting ultrasound lung cornet-tails issued from the pleural line Lung consolidation corresponding to presence of a tissue pattern containing hyperechoic punctiform images representative of air bronchograms. Presence or absence of regional pulmanory blood flow and/or dynamic bronchograms.

  2. Comparaison of the PEEP value set at the start of the non-invasive ventilation session [At the start of the non-invasive ventilation session]

    Comparaison of the PEEP value set (in cmH2O) in both groups

  3. Comparaison of the confort value in both groups [at the 30th minute from the start of the 1st Non-invasive ventilation session]

    Comparaison of the confort value in both groups using the Confort Visual Analog scale (from 0 to 10)

  4. Comparaison of the pain value in both groups [at the 30th minute from the start of the 1st Non-invasive ventilation session]

    Comparaison of the pain value in both groups using the Pain Visual Analog scale (from 0 to 10)

  5. Comparaison of the PaO2/FiO2 ratio in both groups [1 hour after the end of the 1st non-invasive ventilation session]

    Comparaison of the PaO2/FiO2 ratio in both groups

  6. Comparaison of the incidence rate of respiratory aggravation in the 2 groups [Until discharge from intensive care/continuous care or until maximum D7.]

    Comparaison of the incidence rate of respiratory aggravation in the 2 groups

  7. Rate of patients included in the experimental group in whom the use of ultrasound during the initiation of non-invasive ventilation is possible [at the 30th minute from the start of the 1st Non-invasive ventilation session]

    Rate of patients included in the experimental group in whom the use of ultrasound during the initiation of NIV is possible

  8. PaO2/FiO2 ratio in both groups in patients with pulmonary consolidation [at the 30th minute from the start of the 1st Non-invasive ventilation session]

    PaO2/FiO2 ratio in both groups in patients with pulmonary consolidation

  9. PaO2/FiO2 ratio in both groups in patients with pleural effusion [at the 30th minute from the start of the 1st Non-invasive ventilation session]

    PaO2/FiO2 ratio in the 2 groups in patients with pleural effusion

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients aged 18 or more

  • Admitted to intensive care or continuing care for 72 hours or less for blunt chest trauma, defined by the presence of at least one of the following elements on the initial CT scan: fracture(s) of rib(s) / fracture(s) of the sternum / pulmonary contusion / hemothorax

  • Acute hypoxemic respiratory failure defined by the administration of oxygen at least 3 L/min with nasal cannula or FiO2≥30% if high flow oxygen therapy.

  • Patient with a functional arterial catheter for blood tests

Exclusion Criteria:
  • Acute respiratory distress, defined by the presence of at least one of the following clinical signs: respiratory rate ˃ 35 / use of accessory inspirators / paradoxal abdominal or thoracic motion

  • Imminent need for invasive mechanical ventilation

  • Usual contraindication to non-invasive ventilation (undrained pneumothorax, trauma to the face, vigilance disorders, digestive bleeding, hemodynamic instability, intolerance)

  • Hypercapnia (PaCO2˃45mmHg)

  • Patient unable to cooperate, communicate

  • Therapeutic limitation

  • Expected length of stay ≤ 48h

  • Severe head trauma

  • Pregnant or breastfeeding women

  • Participation in other clinical research related to respiratory failure/respiratory therapy

  • Vulnerable people

  • Protected adults, under guardianship or curatorship, or unable to give consent

  • Non-affiliated person or beneficiary of a social security scheme

  • Absence of free, informed and written consent, signed by the participant and the investigator

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University Hospital, Montpellier

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Montpellier
ClinicalTrials.gov Identifier:
NCT06072339
Other Study ID Numbers:
  • RECHMPL22_0556
First Posted:
Oct 10, 2023
Last Update Posted:
Oct 10, 2023
Last Verified:
Sep 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Montpellier
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 10, 2023